OncLive Staff

Lecia V. Sequist, MD, MPH, and Zofia Piotrowska, MD, MHS, give their input on how they approach cases that are often encountered in clinic.

We traveled to Phoenix, Arizona, for a State of the Science Summit™ on Genitourinary Cancers, which featured insights from the Mayo Clinic and Benner MD Anderson Cancer Center faculty.

We traveled to Long Island, New York, for a State of the Science Summit™ on Breast Cancer, which featured insights from the NYU Langone’s Perlmutter Cancer Center faculty.

After witnessing 10 years of breakthroughs across the spectrum of cancer care, oncology experts are looking ahead as a new decade begins to capitalize on those wide-ranging therapeutic and diagnostic gains.

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

The FDA has approved olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma.

We traveled to Oklahoma City, Oklahoma, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the Stephenson Cancer Center faculty.

An application has been submitted to the FDA for selinexor for the treatment of patients with relapsed/refractory diffuse large B-Cell lymphoma who have received at least 2 prior multiagent therapies and who are ineligible for stem cell transplantation, including CAR T-cell therapy.

The FDA has approved enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.

Bristol-Myers Squibb has submitted a biologics license application to the FDA seeking approval of the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.

Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.

We traveled to Philadelphia, Pennsylvania, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the University of Pennsylvania faculty.

We traveled to Chicago, Illinois, for a State of the Science Summit™ on Lung Cancer, which featured insights from the University of Chicago faculty.

We traveled to Raleigh, North Carolina, for a State of the Science Summit™ on Breast Cancer, which featured insights from the Duke Cancer Institute faculty.

We sat down with Ajai Chari, MD, and Sundar Jagannath, MD, both of Mount Sinai Hospital, to provide insight on controversial, but critical, questions regarding the merits of quadruplet versus triplet therapy in the newly diagnosed setting, the optimal maintenance approach in high-risk patients, and the data in support of and against initiating treatment in patients with smoldering multiple myeloma.

We traveled to Salt Lake City, Utah, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from the University of Utah and Intermountain Healthcare.

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

The European Commission has approved the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma.

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the University of Pittsburgh Medical Center faculty.

Ruxolitinib met the primary endpoint of the phase III REACH2 trial, improving the overall response rate at day 28 versus best available therapy in patients with in patients with steroid-refractory acute graft-versus-host disease.

In keeping up with the expanding breast cancer treatment armamentarium, we sat down with Jane L. Meisel, MD, and Aditya Bardia, MD, MPH, who shed light on emerging treatment strategies for patients with metastatic triple-negative breast cancer and discussed the optimal timing of genomic testing in women with progressive hormone receptor–positive disease.

Patients with metastatic gastric or gastroesophageal junction cancer had improved overall survival with TAS-102, irrespective of prior gastrectomy.

We traveled to Seattle, Washington, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Seattle Cancer Care Alliance faculty.

We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer, which featured insights from key thought leaders at Carbone Cancer Center of the University of Wisconsin.

OncLive interviewed experts at the State of the Science Summits™ in September 2019 on anticipated research to be presented at the 2019 ESMO Congress.

OncLive interviewed experts at the State of the Science Summits in August 2019 on aspects of care in their field that they wish were publicized more.

Belantamab mafodotin met the primary endpoint of demonstrating a clinically meaningful overall response rate in patients with relapsed/refractory multiple myeloma, according to topline results from the phase II DREAMM-2 trial.

The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer.

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Although immunotherapy has become an important modality for treating non–small cell lung cancer, the development of new strategies for targeting oncogenic drivers of disease in subgroups of patients is moving forward at a brisk pace.